Avanos Medical, Inc.

Good morning ladies and gentlemen and welcome to the Avanos Second Quarter 2025 earnings conference call. At this time all lines are in listen only mode. Following the presentation we will conduct a question and answer session and if at any time during this call you require immediate assistance please press star zero for the operator. I would now like to turn the conference over to Scott Calavan, Chief Financial Officer, please go ahead sir.

Good morning everyone and thanks for joining us. It's my pleasure to welcome you to Avanos 2025 Second Quarter earnings conference call. Presenting today will be Dave Pasitti, CEO who will kick off the call by sharing a few leadership updates. Dave will then provide a high level overview of our Second Quarter results before turning it over to Jason Pickett who has been serving as our interim CFO. Jason will share additional details on these topics, provide an overview of our financial results and affirm our 2025 planning assumptions inclusive of the impact of tariffs. We will finish the call with Q&A. A presentation for today's call is available on the investor section of our website Avanos.com. As a reminder our comments today contain forward looking statements related to the company, our expected performance and current economic conditions including risk related to ongoing tariff negotiations and our industry. No assurance can be given as to future financial results. Actual results could differ materially from those in the forward looking statements. For more information about forward looking statements and the risk factors that could influence future results, please see today's press release and risk factors described in our filings with the SEC. Additionally, we will be referring to adjusted results and outlook. The press release has information on these adjustments and reconciliations to comparable gap financial measures. Now I'll turn the call over to Dave.

Thanks Scott and good morning everyone. I'd like to begin today by addressing the leadership changes that we announced earlier this morning. First it's my great pleasure to announce that Scott Gallivan previously our SVP of strategy and corporate development has been appointed Avanos' new chief financial officer. In his 12 plus years with the company Scott has been instrumental in executing our strategy, identifying and pursuing strategic acquisitions and divestitures to strengthen our portfolio and keeping Avanos focused on the future. His extensive experience navigating complex transactions will be absolutely critical as we build on our transformation efforts. We're excited to welcome him to this role and look forward to his dynamic leadership and valuable contributions. I'd also like to take this opportunity to thank Jason Pickett for serving as our interim CFO while we conducted our search to fill this role. We greatly appreciate his leadership and his commitment to keeping us on the right path during this transitional period. Jason will continue to lead our tax, treasury and accounting functions. Finally, I'm honored to announce I've been appointed to Avanos' board of directors, working alongside our board members to guide Avanos strategic direction and focus on delivering long-term shareholder value will truly be my privilege. Now, we will shift our comments to our quarterly results and outlook. Building off our first quarter results, we delivered a strong second quarter anchored by continued healthy performance of our life-sustaining specialty nutrition system segment, along with continued progress in our opioid-sparing pain management and recovery segment. The demand for our product remains robust and I'm pleased with the foundation laid out for our three-year transformation efforts. During my first 100 days, I've reviewed the initiatives that we were identified and implemented within the transformation journey. I've encouraged by the progress of these initiatives and believe that these are additional opportunities to advance our optimization efforts. While still early in my tenure, I'm confident we can improve our commercial effectiveness through organizational enhancements, innovative and capital-efficient -to-market approaches and strategic partnerships. In addition, I believe there are further operating model improvements and cost reduction opportunities through the organization that we will be addressing in the coming quarters. Next, I'm pleased to share that on July 31st, we closed the sale of our hyaluronic acid product line of business. While we are not disclosing the financial term, we are very pleased with this divestiture, which represents a meaningful step in advancing our transformation strategy and reinforcing our commitment to focus growth in our two strategic segments, specialty nutrition systems and pain management and recovery. Now, turning to our second quarter results. For the quarter, we achieved net sales of 175 million, adjusted for the effects of foreign exchange and the impact of our strategic decision to withdraw from revenue streams that did not meet the return criteria specified by our portfolio transformation priority. Organic sales were up 2% compared to a year ago. Additionally, we regenerated 17 cents of adjusted diluted earnings per share and 17 million of adjusted EBITDA with adjusted gross margins of .7% and SG&A as a percentage of revenue of 45.2%. Finally, due to downward pressure on our market capitalization, we assessed goodwill for impairment during the second quarter and recorded a non-cash impairment charge of 77 million in the pain management and recovery reporting unit. Our overall execution this quarter was solid and the steady progress we made against each of our transformation priorities provides confidence in our ability to achieve the ranges of our 2025 financial guidance. With that, let me turn the call over to Jason, who will further discuss our second quarter financial results as well as our 2025 outlook.

Thanks, Dave. I'll spend the next few minutes discussing our second quarter results at the segment level. Our specialty nutrition systems portfolio continues to deliver above market results, growing 5% organically versus prior year, reaffirming our number one position in long-term, short-term, and neonatal internal feeding. Demand for our long-term internal feeding products remains strong and our underlying growth continues to beat market levels. However, as anticipated and shared during our first quarter earnings call, our second quarter performance was tempered by the timing of distributor orders captured in our first quarter results resulting from our go direct transition in the United Kingdom. Our short-term internal feeding portfolio posted another quarter of double digit growth globally during the second quarter. These results were fueled by the continued expansion of our U.S. CoreTrack standard of care offering, inclusive of our newly launched CoreGrip tube retention system designed to reduce the risk of tube migration and dislodgement. Finally, our neonatal solutions business delivered another excellent quarter growing greater than 12% compared to the prior year. As we had previously signaled, we anticipate lower but still above market growth for our Neomed product line over the next few quarters as we enter the late stages of the in-fit adoption cycle in North America. From a profitability standpoint, operating profit for our specialty nutrition system segment for the second quarter was nearly 18%, reflecting the impact of tariffs and transient unfavorable cost absorption. We believe the dynamics we have just discussed provide a foundation for us to deliver mid single digit organic revenue growth for our specialty nutrition systems portfolio in 2025, driven by core commercial execution, new product innovations, and further global market expansion opportunities. Now turning to our pain management and recovery portfolio. Normalized organic sales for this quarter were up 3.4%, excluding the impact of foreign exchange and our previously announced strategic decision to withdraw from certain low growth, low margin products. Our radio frequency ablation, or RFA business, continues to deliver excellent results, posting near 14% growth this quarter compared to the previous year. We are experiencing sustained growth in our RFA generator capital sales, which enables us to capture higher procedure volumes, especially within our AscentTech and Trident product lines. We credit our renewed ASC strategy and the increasing productivity of our fully deployed new sales structure in supporting these outcomes. Additionally, we are encouraged by the progress of our cool leaf offering internationally, leveraging reimbursement tailwinds in several geographies, including the United Kingdom and Japan. Our surgical pain business was down compared to prior year, but generally in line with our expectations. While the implementation of the reimbursement decision afforded by the No Pain Act is taking longer than anticipated, and we are devoting more effort to understanding and addressing coverage denials, the No Pain Act provides hospitals and caregivers with improved options to administer non-opioid post-surgical pain relief. We are excited to support better patient care through our OnCue and Anvit product line offerings. Finally, our game ready portfolio posted slightly lower revenues than a year ago. We are working to enhance our go-to market model, primarily in North America, to improve performance and expand profitability within our portfolio. Operating profit for our pain management and recovery segment, excluding the non-cash goodwill impairment charge previously mentioned, grew nearly 2 million from a year ago during the second quarter, demonstrating our recent top line and cost management execution. Although we had some mixed results across our pain management and recovery segment during the second quarter, we are encouraged by the continued progress we saw, particularly within our RFA product line, which continues to make solid organic gains. Finally, our hyaluronic acid injections and intravenous infusion product lines reported in corporate and other declined over 20% during the second quarter, primarily due to continued pricing pressure on our three and five shot HA categories. As Dave mentioned a few minutes ago, we divested the HA business at the end of July. Moving to our financial position and liquidity, our balance sheet remains strong and continues to provide us with strategic flexibility with $90 million of cash on hand and $105 million of debt outstanding as of June 30th. We have maintained leverage levels meaningfully below one term for several quarters and will continue to be good stewards of our balance sheet. Free cash flow for the quarter was negative, approximately 4 million, driven by the timing of tax payments, as well as higher capital expenditures supporting our supply chain initiatives. We anticipate generating approximately $40 million of free cash flow for the year, including the impact of tariffs, which I'll address in a few minutes. From a capital allocation standpoint and as we have previously shared, we have closed on two smaller transactions that support our specialty nutrition system strategy and we are actively pursuing acquisitions that align with our returns criteria. Now turning to our 2025 outlook. Given our robust first and second quarter sales performance, along with favorable currency positions, we are reaffirming our full year revenue estimate of $665 million to $685 million, inclusive of the impact of our hyaluronic acid divestiture. We remain confident in our specialty nutrition system segments strength for the duration of the year and continued market share gains in our RFA segment. Now regarding tariffs, while the environment remains volatile and fluid, we still estimate approximately $15 million in incremental tariff related manufacturing costs for the year. Primarily related to products with country of origin from Mexico and China consistent with our initial estimate. As a reminder, in the first quarter, we incurred $1.5 million of tariffs, which were capitalized into inventory and amortized in the second quarter through cost of goods sold. For the second quarter, we incurred over $8 million of tariffs, which we will be expensing in the third quarter. The second quarter tariffs were negatively impacted by increased China origin goods shipments, with some incurring the 145% tariff rate prior to the US administration reducing the China origin tariffs to 30%. Our team continues to implement a range of strategies focused on tariff mitigation actions, including internal cost containment, pricing actions where appropriate, leveraging previously issued temporary tariff exemptions for portions of our portfolio and lobbying efforts with AdvaMed and other third parties that have interactions with the administration. Lastly, we have accelerated supply chain investments and are targeting a complete exit from China source Neomed products by the second half of 2026. As we noted in our first quarter earnings call, we entered 2025 with challenging market conditions for some of our product categories, currency headwinds and other global macroeconomic factors like tariffs. Despite these challenges, currency conditions have improved, our strategic segment growth is healthy, and our cost management discipline remains strong. We still face uncertainty on the full impact of tariffs on our profitability and free cash flow, but we are pleased with our commercial progress thus far this year. As a result, the company is maintaining its 2025 adjusted earnings per share estimate range of 75 cents to 95 cents, inclusive of the impact of our hyaluronic acid divestiture. Operator,

please open the line for questions.

Thank you. Ladies and gentlemen, we will now begin the question and answer session. And if you wish to ask a question, please press star and 1 on your telephone keypad. And we now have our question. This comes from Dan Stother from Citizens, JMP. Your line is now open. Please go ahead and ask your question.

Yeah, great. Thank you for the questions. Congrats on the great quarter. And Scott, congratulations on the new role. First one, just on the 2025 guidance. You reaffirmed a full year on the sales line and that's inclusive of the HA divestiture. So that's impressive and great to see. But I was hoping you'd just give us some more high level color on what you had previously assumed for HA in the second half of 2025 and what that implies for SNS and pain management as we model out the back half of the year. Thanks.

Sure. Thanks, Danny. So, yes, we're pleased to be able to affirm the year inclusive of the impact of HA. Obviously, there's five months of revenue that we're not going to be able to recognize in that business due to the sale. So we're pleased with the performance of our future of SNS and PM&R. Those businesses have continued to perform well. We're not disclosing exactly what the impact would be of the foregone HA revenue, but we are comfortable reaffirming guidance for the top line and bottom line.

Yeah, Danny, I also add currency headwinds are not as material as we'd anticipated. So that's been a great answer that allows us to follow up with

that growth in the strategic segments that we have.

Okay, great. Appreciate that. And then I guess a little bit more specific on the RF ablation business, really strong quarter. You touched on some of the dynamics there, but would still love some more color on what's driving growth there and how sustainable do you feel this is in the second half of 2025 and into 26, just anything you're seeing, any more color would be great.

Yeah. Hi, Danny. This is Dave. A couple of things. One, I've had a chance to be out there with the team and also attended a couple of pain conferences, so I've got a really good and better understanding of the market. And as I spent time with physicians and our customers, as well as our team in the field, you know, I think more and more customers see us as a RF solution company, very dedicated in that area. You know, there's companies with a broader different offerings and pain, but we're very focused on an RF ablation. We have a three tiered offering, which I think also is very complementary to what physicians are trying to do when you look at our total portfolio. So given the fact that we're dedicated to the space, we've been in the space a long time. We now have the three tiered offering. And you know, there's a lot of momentum there on the RF ablation side. And we see that momentum continuing. We're very pleased with the execution of the team in the field and in the portfolio and the progress that we're making. So yes, we I would say feel very good about it and feel good about heading into next year as well. And I do think because we are dedicated to the space, you know, as you know, there's other companies are doing have a broader offering, as I mentioned. But given the fact that we're so focused on it, people see us as the RF company, at least that's a takeaway I have from being in the field. And the offerings are really quite good in terms of having that three tiered solution.

And I think from a numbers perspective, you can see 13, 28% growth quarter over quarter for the RFA. And what we're seeing is with our our increase in our generator sales, which is a great answer, we're also seeing material pull through. So we sell the generator, we're actually selling the higher priced and margined probes that we have. And we're seeing that not just with if you sell our generators, but you have people that keep those generators and they're continuing to buy from us. So again, that comes back to the sales team that's going out there servicing the customers and just being

able to differentiate our products from what's out there.

Great. Thank you for that. And just one last one for me, again, on H.A. Devesture. I guess just, you know, how should we think about how this impacts the income statement longer term, specifically on the gross and operating margin lines? You know, we appreciate that you reiterated the bottom line guide here and understand that there are some other moving parts for the rest of 2025. But, you know, as we look out further, what do you feel is more steady state without H.A. as far as the margin level looks like? Or is it pretty neutral given some of your initiatives that you have in place? Thanks.

Yeah, what I would say, Daniel, is when we looked at what was coming in the back half of the year, we'd mentioned to you that we were running the business more from a cash perspective. So we were trying to maintain the revenue. We were potentially lowering our sales prices to make the business work. So ultimately, when we look at the financials for the rest of the year, not a material impact on the bottom line when it comes to the H.A. Devestiture. We're able to make up anything that we are losing there or on the revenue side with our strong strategic performance in those segments. So H.A. not a material number that we're seeing all the way down to the bottom line.

Yeah, the challenge in that business was not volumes. It was more price. And so obviously, from a profitability perspective, as we continue to see pressure on margins in H.A., the impact there going forward from just EPS and EBITDA perspective is limited.

Great. Thank you very much.

Thank you. And no further questions that came through at this time. I'll now turn the call over back to David Pasitti for closing remarks. Please go ahead, sir.

Yeah, thanks, everyone. Thanks for the questions today. In closing, I'm really proud of the progress Avanos has made in transforming our business as demonstrated by our Hyaluronic Acid Divestiture. I'm generally pleased with our bright future driven by the dedication of our teams and vital role our products really play with our customers, which is great to see and really getting back to patients and back to things that matter. So we appreciate your continued interest in Avanos and thanks again for the questions.

Thank you. This concludes our conference call for today. Thank you all for participating. You may now disconnect.